213 related articles for article (PubMed ID: 32495917)
1. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.
Ding JG; Li J; Hong L; Yu XQ; Ye EL; Sun GQ; Zhang XX; Chen L; Sun QF
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5788-5796. PubMed ID: 32495917
[TBL] [Abstract][Full Text] [Related]
2. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Cao B; Wang Y; Wen D; Liu W; Wang J; Fan G; Ruan L; Song B; Cai Y; Wei M; Li X; Xia J; Chen N; Xiang J; Yu T; Bai T; Xie X; Zhang L; Li C; Yuan Y; Chen H; Li H; Huang H; Tu S; Gong F; Liu Y; Wei Y; Dong C; Zhou F; Gu X; Xu J; Liu Z; Zhang Y; Li H; Shang L; Wang K; Li K; Zhou X; Dong X; Qu Z; Lu S; Hu X; Ruan S; Luo S; Wu J; Peng L; Cheng F; Pan L; Zou J; Jia C; Wang J; Liu X; Wang S; Wu X; Ge Q; He J; Zhan H; Qiu F; Guo L; Huang C; Jaki T; Hayden FG; Horby PW; Zhang D; Wang C
N Engl J Med; 2020 May; 382(19):1787-1799. PubMed ID: 32187464
[TBL] [Abstract][Full Text] [Related]
3. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
Vargas M; Servillo G; Einav S
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
[TBL] [Abstract][Full Text] [Related]
4. Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19.
Chen X; Zhu B; Hong W; Zeng J; He X; Chen J; Zheng H; Qiu S; Deng Y; Chan JCN; Wang J; Zhang Y
Int J Infect Dis; 2020 Sep; 98():252-260. PubMed ID: 32619760
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
Cheng CY; Lee YL; Chen CP; Lin YC; Liu CE; Liao CH; Cheng SH
J Microbiol Immunol Infect; 2020 Jun; 53(3):488-492. PubMed ID: 32331982
[TBL] [Abstract][Full Text] [Related]
6. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.
Zhu Z; Lu Z; Xu T; Chen C; Yang G; Zha T; Lu J; Xue Y
J Infect; 2020 Jul; 81(1):e21-e23. PubMed ID: 32283143
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
[TBL] [Abstract][Full Text] [Related]
8. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics and Factors Associated With Long-Term Viral Excretion in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Single-Center 28-Day Study.
Shi D; Wu W; Wang Q; Xu K; Xie J; Wu J; Lv L; Sheng J; Guo J; Wang K; Fang D; Li Y; Li L
J Infect Dis; 2020 Aug; 222(6):910-918. PubMed ID: 32614392
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and treatment of COVID-19 patients in northeast Chongqing.
Wan S; Xiang Y; Fang W; Zheng Y; Li B; Hu Y; Lang C; Huang D; Sun Q; Xiong Y; Huang X; Lv J; Luo Y; Shen L; Yang H; Huang G; Yang R
J Med Virol; 2020 Jul; 92(7):797-806. PubMed ID: 32198776
[TBL] [Abstract][Full Text] [Related]
11. Skin manifestations associated with the new coronavirus SARS-CoV-2 disease.
Redondo-Sendino Á; González Sánchez IC; de Victoria Fernández B
Med Clin (Barc); 2020 Nov; 155(9):414-415. PubMed ID: 32873395
[No Abstract] [Full Text] [Related]
12. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
[TBL] [Abstract][Full Text] [Related]
13. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice.
Levy C; Lassailly G; Parmentier E; Duburcq T; Mathurin P; Poissy J
Am J Gastroenterol; 2020 Oct; 115(10):1716-1718. PubMed ID: 32858566
[TBL] [Abstract][Full Text] [Related]
14. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients.
Yuan J; Zou R; Zeng L; Kou S; Lan J; Li X; Liang Y; Ding X; Tan G; Tang S; Liu L; Liu Y; Pan Y; Wang Z
Inflamm Res; 2020 Jun; 69(6):599-606. PubMed ID: 32227274
[TBL] [Abstract][Full Text] [Related]
15. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
16. Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2-infected patient.
Stalder G; Alberio L
Blood; 2020 Aug; 136(7):915. PubMed ID: 32790855
[No Abstract] [Full Text] [Related]
17. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32661006
[TBL] [Abstract][Full Text] [Related]
18. Treatment and Outcome of a Patient With Lung Cancer Infected With Severe Acute Respiratory Syndrome Coronavirus-2.
Zhang H; Xie C; Huang Y
J Thorac Oncol; 2020 May; 15(5):e63-e64. PubMed ID: 32147577
[No Abstract] [Full Text] [Related]
19. Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
Owa AB; Owa OT
J Microbiol Immunol Infect; 2020 Oct; 53(5):674-675. PubMed ID: 32474026
[TBL] [Abstract][Full Text] [Related]
20. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.
Young BE; Ong SWX; Kalimuddin S; Low JG; Tan SY; Loh J; Ng OT; Marimuthu K; Ang LW; Mak TM; Lau SK; Anderson DE; Chan KS; Tan TY; Ng TY; Cui L; Said Z; Kurupatham L; Chen MI; Chan M; Vasoo S; Wang LF; Tan BH; Lin RTP; Lee VJM; Leo YS; Lye DC;
JAMA; 2020 Apr; 323(15):1488-1494. PubMed ID: 32125362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]